Lifecore Biomedical, Inc. (NASDAQ:LFCR) Shares Purchased by Barclays PLC

Barclays PLC grew its position in shares of Lifecore Biomedical, Inc. (NASDAQ:LFCR) by 301.7% during the 3rd quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 29,944 shares of the company’s stock after purchasing an additional 22,489 shares during the period. Barclays PLC owned 0.08% of Lifecore Biomedical worth $147,000 at the end of the most recent quarter.

Other hedge funds also recently modified their holdings of the company. State Street Corp boosted its stake in shares of Lifecore Biomedical by 10.2% during the 3rd quarter. State Street Corp now owns 334,360 shares of the company’s stock worth $1,648,000 after purchasing an additional 30,916 shares during the last quarter. Jane Street Group LLC boosted its stake in shares of Lifecore Biomedical by 101.7% during the 3rd quarter. Jane Street Group LLC now owns 36,246 shares of the company’s stock worth $179,000 after purchasing an additional 18,277 shares during the last quarter. BNP Paribas Financial Markets boosted its stake in shares of Lifecore Biomedical by 2,640.5% during the 3rd quarter. BNP Paribas Financial Markets now owns 54,399 shares of the company’s stock worth $268,000 after purchasing an additional 52,414 shares during the last quarter. Marshall Wace LLP boosted its position in shares of Lifecore Biomedical by 87.3% in the second quarter. Marshall Wace LLP now owns 300,120 shares of the company’s stock worth $1,540,000 after acquiring an additional 139,887 shares during the last quarter. Finally, Geode Capital Management LLC boosted its position in shares of Lifecore Biomedical by 10.3% in the third quarter. Geode Capital Management LLC now owns 597,685 shares of the company’s stock worth $2,948,000 after acquiring an additional 55,703 shares during the last quarter. 83.36% of the stock is owned by institutional investors and hedge funds.

Lifecore Biomedical Stock Down 2.0 %

Shares of NASDAQ:LFCR opened at $6.43 on Thursday. The company has a current ratio of 2.32, a quick ratio of 1.21 and a debt-to-equity ratio of 9.21. The company has a fifty day simple moving average of $7.05 and a 200 day simple moving average of $5.92. The firm has a market cap of $238.10 million, a PE ratio of -11.48 and a beta of 0.98. Lifecore Biomedical, Inc. has a 12-month low of $3.68 and a 12-month high of $8.90.

Lifecore Biomedical (NASDAQ:LFCR) last issued its quarterly earnings results on Thursday, January 2nd. The company reported ($0.25) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.27) by $0.02. Lifecore Biomedical had a negative net margin of 12.52% and a negative return on equity of 315.23%. On average, equities research analysts anticipate that Lifecore Biomedical, Inc. will post -1 EPS for the current fiscal year.

Insider Activity

In related news, CEO Paul Josephs acquired 17,000 shares of the business’s stock in a transaction that occurred on Wednesday, January 8th. The shares were acquired at an average cost of $5.74 per share, for a total transaction of $97,580.00. Following the completion of the purchase, the chief executive officer now directly owns 559,717 shares in the company, valued at $3,212,775.58. This trade represents a 3.13 % increase in their ownership of the stock. The acquisition was disclosed in a legal filing with the SEC, which is accessible through the SEC website. Corporate insiders own 28.21% of the company’s stock.

Analyst Upgrades and Downgrades

Several equities research analysts recently issued reports on LFCR shares. Craig Hallum raised their target price on shares of Lifecore Biomedical from $8.00 to $10.00 and gave the stock a “buy” rating in a research report on Friday, November 22nd. Stephens reissued an “equal weight” rating and issued a $6.00 target price on shares of Lifecore Biomedical in a research report on Friday, January 3rd.

About Lifecore Biomedical

Lifecore Biomedical, Inc, together with its subsidiaries, operates as an integrated contract development and manufacturing organization in the United States and internationally. The company engages in the manufacturing of pharmaceutical-grade sodium hyaluronate (HA) in bulk form, as well as formulated and filled syringes and vials for injectable products used in treating a range of medical conditions and procedures.